Pieris Pharmaceuticals (PIRS)
(Delayed Data from NSDQ)
$16.58 USD
-0.66 (-3.83%)
Updated Sep 23, 2024 11:01 AM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Pieris Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 43 | 26 | 31 | 29 | 46 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 43 | 26 | 31 | 29 | 46 |
Selling & Adminstrative & Depr. & Amort Expenses | 73 | 69 | 83 | 63 | 73 |
Income After Depreciation & Amortization | -30 | -43 | -52 | -34 | -27 |
Non-Operating Income | 5 | 10 | 6 | -3 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -25 | -33 | -46 | -37 | -25 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -25 | -33 | -46 | -37 | -25 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -25 | -33 | -46 | -37 | -25 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -28 | -41 | -49 | -32 | -27 |
Depreciation & Amortization (Cash Flow) | 2 | 3 | 2 | 2 | 1 |
Income After Depreciation & Amortization | -30 | -43 | -52 | -34 | -27 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.13 | 0.93 | 0.81 | 0.68 | 0.63 |
Diluted EPS Before Non-Recurring Items | -9.60 | -36.00 | -56.80 | -54.40 | -44.80 |
Diluted Net EPS (GAAP) | -21.60 | -36.00 | -56.80 | -54.40 | -44.80 |
Fiscal Year end for Pieris Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.05 | 1.30 | 19.52 | 20.06 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.05 | 1.30 | 19.52 | 20.06 |
SG&A, R&D, and Dept/Amort Expenses | 4.18 | 5.36 | 5.80 | 31.33 | 17.99 |
Income After SG&A, R&D, and Dept/Amort Expenses | -4.18 | -5.31 | -4.50 | -11.81 | 2.07 |
Non-Operating Income | 0.59 | 0.41 | -0.08 | 1.06 | 1.91 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -3.59 | -4.89 | -4.58 | -10.75 | 3.98 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -3.59 | -4.89 | -4.58 | -10.75 | 3.98 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -3.59 | -4.89 | -4.58 | -10.75 | 3.98 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 1.30 | 1.24 | 1.32 | 1.24 | 1.10 |
Diluted EPS Before Non-Recurring Items | -2.76 | -3.95 | -4.00 | -8.80 | 4.00 |
Diluted Net EPS (GAAP) | -2.76 | -3.95 | -2.40 | -8.80 | 4.00 |